Home・Akciju saraksts・IQVIA Holdings Inc

IQVIA Holdings Inc

Slēgts

SektorsVeselības aprūpe

236.14 -2.23

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

235.3

Max

241.32

Galvenie mērījumi
By Trading Economics
Ienākumi	-17M 258M
Pārdošana	217M 4.4B
P/E Sektora vidējais	30.137 57.002
EPS	2.75
Peļņas marža	5.907
Darbinieki	94,000
EBITDA	-18M 790M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+13.21% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 27. okt.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	4.2B 40B
Iepriekšējā atvēršanas cena	238.37
Iepriekšējā slēgšanas cena	236.14

Ziņu noskaņojums

By Acuity

50%

171 / 340 Rangs Healthcare

IQVIA Holdings Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. aug. 22:01 UTC

IQVIA Holdings Inc. shares are lower in after-market trading, despite broader market gains and a record close for the S&P 500.

2026. g. 12. aug. 19:46 UTC

News

IQVIA Holdings reported $3.2 billion in new bookings for Q2 2026, but shares are trading lower despite strong growth metrics.

2026. g. 11. aug. 22:46 UTC

IQVIA Holdings Inc shares are trading higher in after-market hours, showing strength despite a broader market decline influenced by rising crude oil prices.

2026. g. 10. aug. 23:01 UTC

IQVIA Holdings Inc is trading higher in after-market hours, maintaining a steady upward trajectory and positioning above its 20-day moving average.

2026. g. 8. aug. 00:01 UTC

IQVIA Holdings Inc shares are lower in after-market hours amid broader market concerns over Federal Reserve interest rate policies and a recent weak jobs report.

2026. g. 7. aug. 23:01 UTC

IQVIA Holdings Inc shares are lower in after-market hours, continuing a decline since Friday's close with no specific news identified for the drop.

2026. g. 6. aug. 20:06 UTC

IQVIA Holdings Inc shares are declining today, breaking a trend of higher closes since Wednesday. No specific news was identified to explain this movement.

2026. g. 5. aug. 20:03 UTC

Correlated Moves

News

IQVIA Holdings announced a collaboration with Medera to advance cardiac gene therapies. Positive sentiment from this partnership likely supported shares trading higher today.

2026. g. 4. aug. 23:01 UTC

News

IQVIA Holdings Inc announced a collaboration with Medera to enhance cardiac gene therapies. Shares declined during after-market trading, continuing a trend of lower closes.

2026. g. 3. aug. 20:06 UTC

IQVIA Holdings Inc. shares are lower today, breaking a trend of higher closes since Friday. No specific company news was identified to explain the move.

2026. g. 31. jūl. 19:16 UTC

News

Shares of IQVIA Holdings lower after first-quarter results.

2026. g. 30. jūl. 23:02 UTC

IQVIA Holdings Inc shares are higher in after-market trading, reflecting positive momentum since Thursday's close, despite no specific news driving the movement.

2026. g. 29. jūl. 22:06 UTC

Correlated Moves

IQVIA Holdings shares declined in after-hours trading, reflecting broader market unease following the Federal Reserve's decision to maintain interest rates.

2026. g. 28. jūl. 20:51 UTC

IQVIA Holdings Inc is trading lower in after-market hours, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

2026. g. 27. jūl. 23:12 UTC

IQVIA Holdings Inc. shares are higher in after-market trading, tracking broader gains in European markets, including a rise in the DAX 30 Index.

2026. g. 23. jūl. 20:03 UTC

Correlated Moves

IQVIA Holdings Inc shares are higher, supported by a rise in Thermo Fisher Scientific Inc's stock and positive sentiment in the life sciences sector.

2026. g. 22. jūl. 16:36 UTC

IQVIA Holdings Inc shares are lower today, continuing a trend of declines. Broader market sentiment is affected by rising crude oil prices and geopolitical tensions.

2026. g. 21. jūl. 19:06 UTC

Social Media

Shares of IQVIA Holdings Inc are lower following disappointing first-quarter results. Unusual call options activity exceeding $2 million indicates heightened investor interest.

Salīdzinājums

Cenas izmaiņa

IQVIA Holdings Inc Prognoze

Cenas mērķis

By TipRanks

13.21% augšup

Prognoze 12 mēnešiem

Vidējais 273.43 USD 13.21%

Augstākais 300 USD

Zemākais 240 USD

Pamatojoties uz 16 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi IQVIA Holdings Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

16 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 16 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam IQVIA Holdings Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

171 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.